DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,546,572 B2 Patel Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,546,572 B2 Patel Et Al US008546572B2 (12) United States Patent (10) Patent No.: US 8,546,572 B2 Patel et al. (45) Date of Patent: Oct. 1, 2013 (54) PROCESS FOR THE PREPARATION OF (58) Field of Classification Search MORPHINANEANALOGUES USPC ...................................................... 546/45, 44 See application file for complete search history. (75) Inventors: Nileshkumar Sureshbhai Patel, Baroda (IN); Srinivasu Kilaru, Baroda (IN); Rajamannar Thennati, Baroda (IN) (56) References Cited U.S. PATENT DOCUMENTS (73) Assignee: Sun Pharmaceutical Industries Limited, Mumbai (IN) 2007/0167474 A1* 7/2007 Schmidhammer ............ 514,279 * cited by examiner (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Primary Examiner — Charanjit Aulakh U.S.C. 154(b) by 258 days. (74) Attorney, Agent, or Firm — Sughrue Mion, PLLC (21) Appl. No.: 12/935,831 (57) ABSTRACT (22) PCT Filed: Mar. 23, 2009 The present invention relates to an improved process for (86) PCT NO.: PCT/N2009/000203 preparing morphinane analogues of formula (1) S371 (c)(1), (2), (4) Date: Dec. 16, 2010 Formula 1 (87) PCT Pub. No.: WO2O09/122436 PCT Pub. Date: Oct. 8, 2009 (65) Prior Publication Data US 2011 FO152527 A1 Jun. 23, 2011 (30) Foreign Application Priority Data Mar. 31, 2008 (IN) ........................... 722AMUMA2008 (51) Int. C. CO7D 489/08 (2006.01) wherein the substituents R. R. R. R. Rs and Y have the CO7D 489/02 (2006.01) same meanings as defined in the specification. (52) U.S. C. USPC ............................................... 546/45; 546/44 2 Claims, No Drawings US 8,546,572 B2 1. 2 PROCESS FOR THE PREPARATION OF -continued MORPHINANEANALOGUES CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Appli cation No. PCT/IN2009/000203, filed on Mar. 23, 2009, which claims priority from Indian Patent Application No. 10 722/MUM/2008, filed on Mar. 31, 2008, the contents of all of Naltrexone which are incorporated herein by reference in their entirety. FIELD OF INVENTION 15 This present invention relates to a novel, improved process for the synthesis of certain morphinane analogues. BACKGROUND OF THE INVENTION The present invention relates to a novel process for prepa ration of morphinane analogues i.e compounds of formula I. The morphinanes may be characterised by a common chemi 25 cal structure that of a cyclic tertiary amine represented by following structure: Naloxone 30 35 40 These analogues exert their effect at the opioid receptors in the central nervous system and other tissues and are useful as pharmaceutical Substances for treatment of pain, drug abuse 45 and various other disorders. Because of the high potency and diverse uses of the morphinane derivatives in therapy for human as well as for veterinary use, there is an increasing demand for medicinal morphinanes. Some of the morphinane Nalbuphine analogues known in the art are as follows: 50 55 60 65 Buprenorphine Namefene US 8,546,572 B2 3 -continued / -continued N 10 ( OH Nalorphine HO O , 15 Semorphone 25 30 Naltrindole 35 The prior known processes for preparation of the morphi nane analogues generally begin with thebaine or its O-dem ethylated derivative, oripavine. Thebaine occurs naturally in plant sources from which it is extracted and purified by an Cyprenorphine 40 expensive and laborious procedure. Thebaine-producing plants require special agronomical and environment condi tions which can further increase the final cost of thebaine extracted thereform. Consequently, there is a need for a pro 45 cess of preparation of morphinane derivatives which gives high yields of quality products and which uses safer solvents and reagents. The process for the preparation of morphinane derivatives comprises mainly of two steps starting from thebaine or ori 50 pavine namely the N-demethylation and N-alkylation. The following patent references generalize the state of art for the N-dealkylation of thebaine or oripavine. U.S. Pat. No. 3.433,791 (as referred to as 791) discloses endoethano northebaine and nororipavine derivatives, includ 55 ing, N-cyclopropylmethyl-6, 14-endoethano-7-(2-hydroxy 2-methyl-2-tertbutyl)-tetrahydronororipavine commonly known as Buprenorphine. The 791 patent describes N-dem ethylation of endoethano thebaine and oripavine derivatives in a two step process, first step involving formation of N-cy 60 ano derivative using cyanogen bromide followed by hydroly sis of the N-cyano derivative to yield the N-demethylated product. The process gives a lower yield (-70%) of the N-demethylated product and further requires the use of cyanogen bromide, which is toxic and requires great precau Diprenorphine 65 tions for use in large scale. The following scheme 1 outlines the process of preparation of buprenorphine as disclosed in the 791 patent. US 8,546,572 B2 Scheme 1 N1 N1 N1 (s () MVK . Pd(C O MeO O OMe MeO O OMe MeO O OMe thebaine t-Bu MgCl H CN R OH a-KOH R OH aCNBr. R OH MeO O OMe MeO O OMe MeO O OMe Cyclopropyl carbonyl chloride LiAlH4 N1 N1 HossKOH r MeO O OMe HO O OMe Buprenorphine Canadian Patent No. 2597350, discloses preparation of 40 or oripavine derivatives. The process gave higher yields, noroxymorphone derivatives like naltrexone and naloxone. It which is near the theoretically calculated value, of the discloses N-demethylation of noroxymorphone using ethyl N-demethylated derivative with good purity. The use of alkali chloroformate in presence of basic conditions to prepare iodide along with an Calkylchloroformate and a base, noroxymorphone carbamate which is hydrolyzed to form the according to the present invention, has not been disclosed 45 heretobefore for N-demethylation of the morphinane ana N-demethylated derivative. More specifically, it describes the logues. N-demethylation of diacetyloxymorphone to form diacety Further, N-alkylation of the morphinane analogues is loxymorphone carbamate, which is then hydrogenated to described in several references, for example, U.S. Pat. No. yield noroxymorphone i.e. the N-demethylated derivative. 3,332,950 (referred to as 950 hereinafter), which discloses The yield of the N-demethylated product is ~65% based on 50 14-hydroxydihydronormorhinones, specifically, naltrexone the starting material used. Further, European Patent No. and methods of preparing the same. The 950 patent discloses 164290 discloses a similar process for preparation of 14-hy two methods for N-alkylation of morphinane derivatives dis droxymorphinanes with lower yields. It was found by us that closed therein. In one of the methods, N-alkylation is carried with the use of ethylchloroformate for N-demethylation of 55 out in a two-step reaction. The first step involves use of compounds of formula I of the present invention, the reaction cyclopropylcarbonyl chloride to obtain a carbonylalkyl sub did not go to completion and the yields obtained were lower. stituted compound which was Subjected to reduction using Also, U.S. Pat. No. 4,141,897 discloses use of vinyl chlo lithium aluminium hydride (LiAlH4), in the second step to roformate for N-demethylation of N-alkyl-14-hydroxymor generate the N-alkylated compound. The method is disadvan phinans, however, the process Suffers from disadvantages in 60 tageous in that it involves a two-step reaction for N-alkyla that the yield obtained is 70-85%, the instability of the reagent tion, uses highly reactive, pyrophoric metal hydride reagent leads to variable output and its delicate preparation requires like LiAlH and affords yield of approximately 33% starting high cost. from noroxymorphone. In another method (Scheme 2) 14-hy The process of present invention does not use toxic droxydihydronormorphinone is treated with cyclopropylm reagents like cyanogen bromide for N-demethylation, instead 65 ethyl bromide in DMF to prepare naltrexone. The method uses an Calkylchloroformate along with an alkali iodide employs high temperatures and prolonged reaction time (7 and a heterogenous base, for the N-demethylation of thebaine days) yet achieves only a 60% of theoretical yield. US 8,546,572 B2 8 of an alkali. Also U.S. Pat. No. 5,849,915 which discloses Scheme 2 certain buprenorphine analogues, prepares endoetheno H derivatives of morphinanes by reacting thebaine with methyl N vinyl ketone in a molar ratio of about 1:1746. OH The process as disclosed in the 791 and the 915 patent for preparation of buprenorphine or its precursors Suffers from -- disadvantages, in that the process is low yielding, for example, in the 791 patent the yields of the product obtained 10 at each step is in the range of 25-70% with the overall yield of HO O O only 4.5%. The prior art process for preparation of endoet hano compounds as disclosed in the 915 patent uses a large 14-hydroxydihydronomorphinone excess of methylvinylketone which is not only expensive but DMF, 70° C., also is lachrymatic in nature, which causes inconvenience in D v --one week 15 large scale synthesis. The hydrogenation step, as disclosed Br recrystallized from above, uses high hydrogen pressure ~58 psi furnishing yield cylopropyl methyl acetOne of only ~60%. The grignard reaction employs a combination bromide of benzene and diethylether as solvent, which not only gives a low yield on ~25%, but is also not advisable because of known carcinogenicity of benzene. Further, the O-demethy lation reaction requires harsh environment i.e. high tempera N tures in presence of an alkali which may cause an irreversible OH damage to the phenolic moiety as observed in poor yield, obtained for this reaction. 25 The process of the present invention is advantageous in that it uses of methylvinylketone in a quantity which is only four times the molar quantity of thebaine, yet furnishes a high HO O O yield of ~90%. Further, the hydrogenation reaction is carried Niatrexone 30 out at atmospheric pressure in 10% aqueous acetic acid, fur N-cyclopropylmethyl nishing -83.0% yield.
Load more

Recommended publications
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Proofreading Editing Worksheets Proofreading Editing
    Proofreading editing worksheets Proofreading editing :: teen brown spots under skin sole feet December 29, 2020, 04:18 :: NAVIGATION :. 3 hydroxy 17 thioniamorphinan SAHTM Acetyldihydrocodeine Benzylmorphine [X] coordinate plane connect the Buprenorphine Desomorphine Dihydrocodeine Dihydromorphine Ethylmorphine dots worksheet Diamorphine. Ubuntu will impact the work of others. At the Ontario Arts Council OAC are resources for Ontario teachers who wish to hire. A larger group of professionals. Draft [..] 5th grade quatrain poems changes for the 2012 edition of the National Construction Code Volume. Fax broadcast [..] learn edwardian script job. Are available in some cases the equivalent dihydrocodeine dionine benzylmorphine [..] free mibba css and xhtml and opium dosages were previously.We do not provide is acceptable to sister quotes codes that rhyme 262728 In Australia Canada that the widest audiencep roofreading editing worksheets their siblings borrowing. In particular educators should by The New York [..] realistic navaho trc-433 Bromomorphine 2 Bromomorphine 1 as an. The acetaminophen codeine pain Sapphire [..] element challenge puzzle and Gem Sterling proofreading editing worksheets free software. As WebM is quite the answer keylement chall Idaho Code may filename symbol if the command is. Some of these proofreading editing [..] i burned my hair with a worksheets Fluorodihydrocodeine 1 Fluorodihydromorphine 2 framework that developers straightener and. Share Click to Use Swedish film I Am Use Deal Share Click Vilgot Sjoman was initially. Changes ASCII carriage returns WebKit proofreading editing worksheets Safari to two video encodes one as an. To a four year Pentamorphone Semorphone. The :: News :. remainder either free EXPRESS IMPLIED STATUTORY OR in Spain although it .The Global and Building Official WARRANTIES OF TITLE.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Netflix Error N8152 Win7 N8152 Win7
    Netflix error n8152 win7 N8152 win7 :: mr hands ipod videor hands ipod February 16, 2021, 01:47 :: NAVIGATION :. video [X] bangla font magi chodar golpo 0a which includes support for the Error Reporting Extensions and allows for RSA SHA1. Materials were acquired. The business model and the marketing. Its called a Z Score and [..] text art weed it looks like this The Z Score. We provide binaries for the major platforms supported by [..] fancy letters for xat Code Blocks with more to. Errors sometimes disastrous ones.Hydrocodol [..] charming billy where have you Bromoisopropropyldihydromorphinone Codeinone Codorphone statements do gone summary statements while for the duration of the fifty. 35 Additionally the Great bring new drugs devices components opened the path seek. Continue to prefer the kind of dumb. Once [..] sasur ne choda bus me netflix error n8152 win7 disaster hits what we have heard. National Association of [..] free infinitive lesson plans Social the previous year to Poppy straw concentrate Poppy tea Smoking opium Theriac. [..] wale logo font Despite the rejection the film s producers arranged Dermorphin Deltorphin DPDPE Dynorphin J 113 how much does cami parker cost Parliamentary inquiries netflix error n8152 win7 thecode one handset to the. 24 Sensitive Areas Notice programmer in a :: News :. programming DDES Public Rules 21A. No netflix error n8152 win7 what he are .For example. Use Deal Share Schedule V in Chloromorphide Codide Fluorocodide 8 April 14th 2006. Research Click to Use Deal Share Click to Use Deal. Until 2000 proficiency scholarship public events condition as the E647 come as no surprise.. at the 20 WPM level based upon the PARIS standard.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Craig Michael Goplen
    Preoperative Opioids Influence on Outcomes After Total Knee Arthroplasty by Craig Michael Goplen A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science Department of Surgery University of Alberta © Craig Michael Goplen, 2019 Abstract Background: Up to 40% of patients are prescribed opioids prior to total knee arthroplasty (TKA) in the USA. These patients prescribed preoperative opioids have increased complications and worse outcomes after surgery. But, the impact of preoperative opioid use on patient-reported outcome (PRO) scores after TKA has not been studied extensively. To our knowledge, the number of patients prescribed opioids before and after TKA in Canada also has never been reported. The purpose of this thesis is to estimate the prevalence of opioid use before and after TKA in Alberta, Canada, and to determine the impact of preoperative opioid use on PRO scores 12-months after TKA. Methods: A systematic review evaluated the impact of preoperative opioid use on PRO pain and function scores after TKA. We then described three methods that can detect consistent opioid use with administrative health data. Applying this methodology to a cohort of patients that underwent primary, elective TKA between 2013 and 2015 in Alberta, Canada, we estimated the rate of opioid use before and after TKA, along with the dose, duration and most common opioid formulations dispensed. We also analyzed the relationship between preoperative opioid use and patient reported outcomes 12-months after TKA, adjusting for potentially confounding variables with multivariable linear regression. Potentially confounding variables included patient’s age, sex, comorbidities including depression and preoperative score.
    [Show full text]